The Technical Analyst
Repro Med Systems Inc [KRMD]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Instruments & Supplies
Repro Med Systems Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.80% $2.20
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 102.46 mill |
| EPS: | -0.300 |
| P/E: | -7.33 |
| Earnings Date: | Mar 06, 2024 |
| SharesOutstanding: | 46.57 mill |
| Avg Daily Volume: | 0.0974 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.33 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.22x |
| Company: PE -7.33 | industry: PE 33.06 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-2.17 (-198.56%) $-4.37 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.06 - 2.34 ( +/- 6.36%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-31 | Manko Joseph M. Jr. | Buy | 6 329 | Common Stock |
| 2024-03-31 | Wholihan Edward | Buy | 6 329 | Common Stock |
| 2024-03-31 | Matin Shahriar | Buy | 6 329 | Common Stock |
| 2024-03-31 | French Donna | Buy | 6 329 | Common Stock |
| 2024-03-31 | Fletcher R John | Buy | 9 493 | Common Stock |
| INSIDER POWER |
|---|
| -34.73 |
| Last 100 transactions |
| Buy: 2 490 287 | Sell: 4 243 724 |
Forecast:
16:00 - $2.17
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.17
Forecast 2: 16:00 - $2.17
Forecast 3: 16:00 - $2.17
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.20 (2.80% ) |
| Volume | 0.0793 mill |
| Avg. Vol. | 0.0974 mill |
| % of Avg. Vol | 81.44 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KRMD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
KRMD
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
Latest Press Releases
2024-04-17 07:00:00 - Press Release
Koru Medical Systems To Report First Quarter 2024 Financial Results On May 1, 2024
Mahwah, n.j.--(business wire)--koru medical systems (nasdaq: krmd) (“koru medical” or the “company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the company will report first quarter 2024 financial results on wednesday, may 1, 2024. koru medical's management will host a conference call and webcast at 4:30 p.m. et that day to discuss the fina.
2024-04-11 16:05:00 - Press Release
Koru Medical Systems Announces Successful Appeal In Eu Notified Body Review
Mahwah, n.j.--(business wire)--koru medical systems, inc. (nasdaq: krmd) (“koru medical” or the “company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a successful appeal related to an ongoing audit by its notified body in the eu, the british standards institute (bsi). the company's appeal of an assessment report from bsi regarding a recommendati.
2024-03-18 17:24:00 - Press Release
Koru Medical Systems To Present Data Demonstrating 97% Adherence On Its Freedom Infusion System For Large Volume Subcutaneous Administration At Nhia 2024 Conference
Mahwah, n.j.--(business wire)--koru medical systems, inc. (nasdaq: krmd) (“koru medical” or the “company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce data on the impact of the freedom infusion system on subcutaneous immunoglobulin (scig) therapy for primary immunodeficiency diseases (pidd) to be presented at the national home infusion ass.
2024-03-13 16:05:00 - Press Release
Koru Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, And 2024 Guidance
Mahwah, n.j.--(business wire)--koru medical systems, inc. (nasdaq: krmd) ("koru medical" or the "company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended december 31, 2023. the company also issued guidance for the full year 2024. recent highlights fourth quarter 2023 net revenues of $7.2 mi.
2024-03-11 16:05:00 - Press Release
Koru Medical Systems Announces A Feasibility Study To Enter Ambulatory Infusion Settings With A Commercialized Biologic
Mahwah, n.j.--(business wire)--koru medical systems, inc. (nasdaq: krmd) (“koru medical” or the “company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical manufacturer to initiate a feasibility study with koru's freedom infusion system for an already commercialized rare disease therapy. upon successful com.
Latest News
2024-03-28 14:28:50 - InvestorPlace
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.
2024-03-18 17:24:00 - Business Wire
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce data on the impact of the Freedom Infusion System on subcutaneous immunoglobulin (SCIg) therapy for primary immunodeficiency diseases (PIDD) to be presented at the National Home Infusion Ass.
2024-03-13 20:27:03 - Seeking Alpha
KORU Medical Systems, Inc. (KRMD) Q4 2023 Earnings Call Transcript
2024-03-12 09:26:09 - Zacks Investment Research
KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion
One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.
2023-11-08 20:12:14 - Seeking Alpha
KORU Medical Systems, Inc. (KRMD) Q3 2023 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Linda Tharby - Chief Executive Officer and President, Director Tom Adams - Chief Medical Officer Conference Call Participants Caitlin Cronin - Canaccord Genuity Joseph Downing - Piper Sandler Frank Takkinen - Lake Street Capital Operator Good day. And welcome to the KORU Medical Systems Third Quarter 2023 Earnings Call.
2023-10-05 07:05:00 - Business Wire
KORU Medical Systems to Present Two Abstracts at the Immunoglobulin National Society 2023 National Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, is pleased to announce its participation in the Immunoglobulin National Society (“IGNS”) 2023 National Conference, taking place in Denver, Colorado from October 5th to 8th. K.
2023-08-09 20:21:05 - Seeking Alpha
KORU Medical Systems, Inc. (KRMD) Q2 2023 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Linda Tharby - President and CEO Tom Adams - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Caitlin Cronin - Canaccord Genuity Operator Greetings and welcome to the KORU Medical Systems Second Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participants are in listen-only mode.
2023-05-07 07:42:27 - Seeking Alpha
KORU Medical Systems, Inc. (KRMD) Q1 2023 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Gregory Chodaczek - Gilmartin Group Linda Tharby - President, CEO & Director Thomas Adams - Interim CFO, Secretary & Treasurer Conference Call Participants Jason Bednar - Piper Sandler & Co. Alexander Nowak - Craig-Hallum Operator Greetings, and welcome to the KORU Medical Systems First Quarter 2023 Earnings Call. During the presentation, all participants will be in a listen-only mode.
2023-05-04 19:01:36 - Zacks Investment Research
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.
2023-04-21 07:01:00 - Business Wire
KORU Medical Systems to Report First Quarter Financial Results on May 4, 2023
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will report first quarter 2023 financial results on Thursday, May 4, 2023. KORU Medical's management will host a conference call and webcast at 4:30 p.m.